Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 7, 2023
Discovery & Translation

Smaller gene editors, Resilience’s cell-free antibody discovery platform and more

BioCentury’s roundup of translational innovations
BioCentury | Nov 19, 2015
Distillery Therapeutics

Therapeutics: G protein-coupled receptor 183 (GPR183; EBI2)

BioCentury | May 1, 2014
Distillery Techniques

Technology: Drug platforms

BioCentury | Aug 18, 2011
Targets & Mechanisms

EBI2: the race is on

BioCentury | Aug 11, 2011
Distillery Therapeutics

Indication: Autoimmune disease

BioCentury | Dec 4, 2008
Distillery Therapeutics

Indication: Cancer

Items per page:
1 - 6 of 6
Help Center
Username
Request a Demo
Request Training
Ask a Question